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Introduction
BMP2/4 signaling is essential for embryonic development, 
and is also involved in tissue homeostasis and cancer.1-8 It plays 
a role in thymus morphogenesis and T-cell differentiation.9-16 
While BMP2/4 signaling has been shown to be necessary for nor-
mal thymus organogenesis in vivo,17,18 the evidence for BMP2/4 
involvement in thymocyte differentiation is based on in vitro 
studies.9-11 Thus, the physiological role of the pathway in thymo-
cyte differentiation remains unclear.
BMP2 and 4 ligands signal to target cells via the forma-
tion of complexes with type I (BMPRIA, BMPRIB and ALK2, 
also known as ALK3, ALK6, and ACVR1, respectively) and 
II (BMPRII, ActRII, and ActRIIB) transmembrane recep-
tors. BMP2/4 ligands bind to type II receptors, which recruit 
and phosphorylate any of the 3 type I receptors. Alternatively, 
BPM2/4 can bind first to type I receptors and then recruit 
type II receptors. Phosphorylated type I receptors transduce 
the BMP2/4 signal to the nucleus via the phosphorylation of 
receptor Smads (Smad-1, -5, or -8), which, in turn, recruit the 
co-Smad (Smad-4), translocate to the nucleus, and regulate gene 
expression.19
Suppression of BMP2/4 signaling in the epithelium and mes-
enchymal cells of the thymus anlage, achieved by transgenic 
expression of the BMP2/4 inhibitor Noggin in thymic epithe-
lium, driven by the FoxN1 promoter, resulted in a thymus of 
reduced size, ectopically located in the neck. Despite this effect 
on thymus size and location, analysis of newborn thymocytes did 
not reveal a defect in thymocyte differentiation, proliferation or 
apoptosis.17 Targeted deletion of BMP4 from the thymus epithe-
lium also revealed that normal BMP4 signaling at the early stages 
of thymus anlage development is necessary for migration of the 
organ to its final location and normal organ morphogenesis and 
size. Loss of BMP4 signaling also resulted in delayed colonization 
of the organ by common lymphoid progenitors.18 Targeted dele-
tion of BMPRIA in the thymus epithelium, either early or late 
in thymus development, resulted in a morphologically normal 
organ of reduced size.18
During embryonic development, blood-borne progenitor cells 
of hematopoietic lineage migrate into an undeveloped thymic 
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BMp2/4 signaling is required for embryogenesis and involved in thymus morphogenesis and t-lineage differentia-
tion. In vitro experiments have shown that treatment of thymus explants with exogenous BMp4 negatively regulated 
differentiation of early thymocyte progenitors and the transition from CD4−CD8− (DN) to CD4+CD8+ (Dp). Here we 
show that in vivo BMp2/4 signaling is required for fetal thymocyte progenitor homeostasis and expansion, but negatively 
regulates differentiation from DN to Dp cell. Unexpectedly, conditional deletion of BMpRIA from fetal thymocytes (using 
the Cre-loxp system and directing excision to hematopoietic lineage cells with the Vav promoter) demonstrated that 
physiological levels of BMp2/4 signaling directly to thymocytes through BMpRIA are required for normal differentiation 
and expansion of early fetal DN thymocytes. In contrast, the arrest in early thymocyte progenitor differentiation caused 
by exogenous BMp4 treatment of thymus explants is induced in part by direct signaling to thymocytes through BMpRIA, 
and in part by indirect signaling through non-hematopoietic cells. Analysis of the transition from fetal DN to Dp cell, both 
by ex vivo analysis of conditional BMpRIA-deficient thymocytes and by treatment of thymus explants with the BMp4-
inhibitor Noggin demonstrated that BMp2/4 signaling is a negative regulator at this stage. We showed that at this stage 
of fetal t-cell development BMp2/4 signals directly to thymocytes through BMpRIA.
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anlage. Thymocytes and thymus develop synchronously, requir-
ing bidirectional signals for organ morphogenesis and thymo-
cyte development. Progenitor cells migrate into the thymus and 
progress through tightly regulated developmental stages as they 
mature into αβT cells.20 The stages of thymocyte development 
can be phenotypically identified by the expression of the cell 
surface markers CD4 and CD8. Immature CD4−CD8− double-
negative (DN) cells give rise to the CD4+CD8+ double-positive 
(DP) population, which differentiate into mature CD4+ or CD8+ 
single positive mature T cells that migrate out of the thymus 
to the secondary lymphoid organs. The DN population can 
be further subdivided by cell surface expression of CD44 and 
CD25: CD44+CD25− (DN1) cells give rise to the CD44+CD25+ 
(DN2) population, which then downregulates CD44 to become 
CD44−CD25+ (DN3) and finally downregulates CD25 to 
become CD44−CD25− (DN4).
Previous in vitro studies indicated that BMP2/4 negatively 
regulated thymocyte differentiation at 2 distinct developmental 
stages. Treatment of fetal thymus organ cultures (FTOCs) with 
recombinant BMP4 arrested thymocyte differentiation at the 
DN1 stage9,11 and at the transition from DN to DP cell.10,11 In 
addition, treatment with the BMP2/4 inhibitor Noggin acceler-
ated development to the DP stage9,10 and increased the percent-
age of CD2+ DN thymocytes.9 These experiments showed that 
under physiological conditions, BMP2/4 negatively regulates the 
transition from DN to DP cell. Tsai and colleagues11 used thy-
mus reaggregation experiments to investigate the contribution 
of stromal and thymocyte-intrinsic signaling by BMP4 to arrest 
differentiation at the DN1 stage and 
at the DN to DP transition. Their data 
showed that BMP2/4 signaling to both 
thymocytes and stroma are involved in 
BMP2/4’s regulation of thymocyte differ-
entiation, and suggested that while at the 
DN1 stage, BMP4 is exerting its effects 
by signaling both directly to thymocytes 
and indirectly via the stroma, at the DN 
to DP transition, the effect of BMP4 sig-
naling is indirect and mediated by the 
stroma alone.
To investigate the physiological role 
of BMP2/4 signaling during thymocyte 
development, we studied the effect of tar-
geted deletion of BMPRIA in the hemato-
poietic lineage, using the Cre-loxP system 
and the Vav promoter for the expression 
of Cre. This approach allowed us to 
investigate thymocyte development in the 
absence of direct BMP2/4 signaling to 
thymocytes, while indirect signaling via 
the stroma was not impaired.
Results
Expression of BMP2/4 receptors in 
fetal and adult thymocyte subsets
To assess the potential of thymocytes 
to receive and respond to BMP2/4 signal, 
we analyzed the expression of BMP recep-
tors IA (BMPRIA), IB (BMPRIB) and II 
(BMPRII) in fetal (E16.5) and adult CD4−
CD8− double-negative (DN1–4) thymo-
cyte subsets, CD4+CD8+ double positive 
(DP) and CD4+ or CD8+ single positive 
(SP) thymocyte subsets by quantitative 
(q) RT-PCR. We detected expression of 
Bmpr1a and Bmpr2 in both fetal (Fig. 1A) 
and adult (Fig. 1B) thymocytes. Both 
receptors were differentially expressed 
during thymocyte development, and their 
Figure 1. expression of BMp2/4 receptors IA and II in thymocytes. (A) Graphs show transcription of 
Bmpr1a (left) and Bmpr2 (right) in sorted e16.5 C57BL/6 fetal thymocyte populations. Graphs rep-
resent transcription of the 2 genes normalized by transcription of Hprt. (B) As in (A), but for adult 
thymocytes. (C) expression of Smad7 (left) and Alk2 (right) in sorted adult thymocyte populations, 
derived from microarray data from ImmGen. Graphs show transcription of the genes relative to Hprt 
transcription. Values represent the unlogged hybridization intensity value for the relevant probe-
set for each gene divided by the corresponding value for Hprt. Crosses denote hybridization intensi-
ties below the ImmGen threshold value of 120, i.e., absence of significant expression of the gene of 
interest in the population.
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expression profiles differed between fetal and adult thymocytes. 
In fetal thymocytes both receptors were expressed in all subsets, 
and their expression peaked at the CD8+ immature SP and DP 
stage (Fig. 1A). The expression of both receptors in all subsets 
was lower in adult compared with fetal thymocytes. Expression 
of BMPRIA was detected in adult DN1 cells, was not detected in 
DN2 cells, was detected at very low levels in DN3 and DN4 cells, 
and its expression increased in DP, CD4+, and CD8+ SP cells 
(Fig. 1B). The Bmpr2 expression pattern was similar (Fig. 1B). 
We were not able to detect expression of Bmpr1b in any thymo-
cyte subset (data not shown). This was consistent with microar-
ray expression data from sorted thymocyte populations available 
in the ImmGen database,21 in which expression of BMPR1B was 
not detected in any thymocyte population. We also consulted the 
ImmGen database for expression of the type I receptor Alk2 and 
the Smad transcription factors in sorted thymocyte populations 
from DN1 to DP, CD4+, and CD8+ SP. Smad4 and Smad5 were 
highly expressed in all populations, whereas Smad1 and Smad9 
were expressed at lower, but detectable levels in all populations. 
Smad 6 expression was not detected. Interestingly, Smad7, which 
is known to inhibit the BMP pathway, was highly expressed in 
the DN1 population, and significantly downregulated step-wise 
from DN1 to each subsequent DN population (Fig. 1C). Alk2 
expression was below threshold value in all thymocyte subsets 
(Fig. 1C). 
Thymus composition of adult BMPRIA conditional knock-
out mouse
We and others have previously published in vitro data indicat-
ing a role for BMP2/4 signaling in thymocyte development.9-11 
To assess in vivo the involvement of BMP2/4 signaling we 
examined the thymus of adult BMPRIA conditional knockout 
(BMPRIAcon-ko) mice, in which the expression of BMPRIA 
was defective in T-lineage cells, but normal in thymus epithelial 
cells. BMP2/4 signal reception and processing requires a complex 
of a type II BMP receptor with either one of BMPR IA, IB, or 
ALK2.19 We did not detect Bmpr1b or Alk2 expression in thymo-
cyte subsets (data not shown). We can therefore safely assume 
that BMPRIA-deficient thymocytes are unable to transduce 
BMP2/4 signals, since in the BMPRIAcon-ko thymocytes none 
of the type I receptors are expressed, but at least one is neces-
sary for BMP2/4 signaling. To ablate the expression of BMPRIA 
in thymocytes we used mice homozygous for the floxed Bmpr1a 
allele22 expressing Cre under the control of the Vav promoter, 
directing expression to all hematopoietic lineage cells.23 In these 
BMPRIAcon-ko mice exon 2 of Bmpr1a is flanked by loxP sites, 
and the exon is excised in cells expressing Cre, i.e., hematopoi-
etic lineage cells, including even the earliest stages of thymocyte 
development.23 The defective BMPRIA produced lacks the ligand 
binding domain and is therefore not able to activate and signal 
in response to the presence of BMP2/4. BMPRII can form a 
homodimer, but ligand binding is very poor, so BMPRIAcon-ko 
cells will transduce very little or no BMP signal.24
We found that there was no difference in the number of cells 
between BMPRIAcon-ko (Bmpr1a[flox/flox], VavCre+) adult 
thymus and WT (Bmpr1a[flox/flox], VavCre-) littermates (data 
not shown), and cell subset composition was normal. We observed 
no significant differences between BMPRIAcon-ko and WT lit-
termate thymi in cell number or the percentages of cells at the 
DN, DP, CD4+ SP, or CD8+ SP (Fig. 2A) and DN1–4 (data not 
shown). We also analyzed the expression profiles of CD5, CD3 
(Fig. 2B and C), CD24, CD2, and CD69 (data not shown) in 
different thymocyte cell subsets and found no difference between 
genotypes. The fact that conditional deletion of BMPRIA from 
thymocytes made no measurable impact on the composition of 
the adult thymus populations is consistent with the low level 
expression of BMPRIA in adult thymocytes (Fig. 1B), and 
absence of the alternative receptors BMPRIB (ImmGen data, and 
data not shown) and ALK2 (ImmGen data, Fig. 1C). However, 
to confirm that BMPRIB and/or ALK2 were not upregulated 
in BMPR1A-deficient thymocytes and compensating for the 
absence of BMPRIA, we analyzed Bmpr1b and Alk2 expression 
in BMPRIAcon-ko and WT littermate thymocytes, compared 
with expression in embryo head (Fig. 2D). We found no expres-
sion of Bmpr1b and Alk2 in WT thymocytes and no upregulation 
of Bmpr1b and Alk2 in the absence of BMPRIA, suggesting that 
the pathway is not important for adult thymocytes.
Fetal development of BMPRIA-deficient thymocytes
Since BMPRIA is more highly expressed in fetal thymocytes 
(Fig. 1A), we investigated the impact of absence of BMP2/4 sig-
naling on fetal thymocyte development in vivo. To this end, we 
followed the development of BMPRIA-deficient fetal thymo-
cytes at consecutive embryonic days (E), E13.5 to E16.5.
On E13.5, when the thymus is exclusively composed of DN1 
and DN2 cells, we detected no differences in thymocyte num-
ber or DN1/DN2 percentages (Fig. 3A and 3B and C, respec-
tively). On day E14.5, when DN3 and DN4 subsets first develop, 
the number of thymocytes was reduced in the BMPRIAcon-ko 
embryos by 60% on average compared with their WT littermates 
(Fig. 3D). While all subset cell numbers were on average reduced 
in the BMPRIAcon-ko thymi compared with WT, the DN3 sub-
set showed the largest reduction (Fig. 3E). On average, the per-
centage of DN1 and DN2 cells was increased and DN3 reduced 
in BMPRIAcon-ko thymi compared with WT, while DN4 cell 
percentages did not differ between genotypes (Fig. 3F). On E15.5 
the number of thymocytes was still reduced in BMPRIAcon-ko 
compared with WT (Fig. 3G).
At E16.5, when DP cells first appear, thymocyte cell number in 
BMPRIAcon-ko thymi had recovered (Fig. 4A), and the propor-
tions of DN1-DN4, total DN, immature CD8+ (CD8ISP), DP, 
and CD4+ subsets did not differ between genotypes (Fig. 4B and 
C). Given that thymocyte number recovered between E15.5 and 
E16.5, we tested if BMPRIA-deficient thymocytes expand faster 
than WT. We cultured BMPRIAcon-ko and WT E15.5 fetal 
thymus explants for 7 days. The BMPRIAcon-ko fetal thymic 
organ culture (FTOC)s expanded on average ~5-fold, whereas 
WT FTOC expanded less than 2-fold, showing that BMPRIA 
expression by DN thymocytes is required for negative regulation 
of the transition to DP by BMP signaling (Fig. 4D and E).
Impact of BMPRIA thymocyte-specific deletion on BMP4-
induced arrest of differentiation from DN1 to DN3
We have previously shown that the development of thy-
mocytes in FTOCs treated with BMP4 is partially arrested 
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at the DN1 stage.9 It remains unclear whether 
this effect can be attributed to BMP4 signal-
ing directly to the thymocytes, indirectly via 
the thymus stroma, or to a combination of 
direct and indirect signaling. To address this 
question, we treated WT and BMPRIAcon-ko 
E14.5 FTOCs for 3 days with BMP4 and com-
pared the development of the thymocytes of 
different genotypes to the control untreated 
cultures (Fig. 5A). As previously observed, in 
the WT FTOCs the percentage of DN1 cells 
was increased by ~6-fold on average, from 1.1% 
in the control cultures to 6.1% in the BMP4 
treated ones. DN1 percentage increased also in 
BMPRIAcon-ko treated vs. control FTOCs but 
by approximately 3-fold, from 1.1% in the con-
trol to 3.1% in the treated cultures (Fig. 5B). 
The percentage of DN1 in the control FTOCs 
did not differ between genotypes, while the 
percentages of DN1 cells in the BMP4-treated 
FTOCs differed significantly between geno-
types (P = 0.043). No significant differences 
were observed in the percentage of DN2 cells 
either between control and treated cultures or 
between genotypes (Fig. 5B). We observed a 
significant decrease in the DN3 percentage 
(75% to 64% in WT FTOCs and 76% to 67% 
in BMPRIAcon-ko FTOCs) in BMP4-treated 
compared with control FTOCs of both geno-
types (Fig. 5B). No significant differences were 
observed for DN2-DN4 subset percentages 
between genotypes.
We previously showed that BMP4 treatment 
increases the ratio of DN1/DN3 cells.9 Here, we 
found that the ratio of DN1/DN3 was signifi-
cantly lower in BMPRIAcon-ko BMP4 treated 
FTOCs compared with their WT counterparts 
(Fig. 5C). Our data therefore shows that while 
BMP4 treatment arrested the development of 
BMPRIAcon-ko thymocytes at the DN1 stage, 
this effect was weaker compared with that on 
WT thymocytes, and therefore that BMP4 is 
signaling both directly to the DN1 thymocytes 
and indirectly via the stroma.
Figure  2. Analysis of adult BMpRIAcon-ko and Wt 
thymi (A) FACS profiles of CD4 and CD8 cell sur-
face expression in adult Wt (left, Bmpr1a[flox/flox] 
VavCre-) and BMpRIAcon-ko (right, Bmpr1a[flox/flox] 
VavCre+) thymocytes. (B and C) expression of CD5 (B) 
and CD3 (C) in CD4Sp (top panels) and CD8 Sp (lower 
panels) Wt (left) and BMpRIAcon-ko (right) thymo-
cytes. (D) expression of Hprt (left), Bmpr1b (middle), 
and Alk2 (right) in Wt embryo head and adult thy-
mocytes from BMpRIA-con-ko and Wt, positively 
selected for thy1 expression. expression is shown 
relative to embryo head (eH).
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Impact of thymocyte-specific BMPRIA deletion on differ-
entiation from DN to DP
We and others have previously shown that BMP4 treatment 
negatively regulated the transition of DN cells to the DP stage.9-
11 We analyzed thymocyte subset composition of control and 
BMP4-treated WT and BMPRIAcon-ko FTOC. We found that 
BMP4 treatment delayed development of DN to DP cells in both 
WT and BMPRIAcon-ko cultures as shown by increased per-
centages of DN subsets in the BMP4 treated FTOCs compared 
with control cultures (values above 1 for DN subset, Fig. 6A). 
Figure 3. Analysis of e13.5 and e14.5 fetal BMpRIAcon-ko and Wt thymi. (A) Graph representing mean number of cells recovered from e13.5 Wt (open 
bar) and BMpRIAcon-ko (dark bar) thymi. Wt n = 5, BMpRIAcon-ko n = 3. (B) FACS profiles of CD44 and CD25 cell surface expression in e13.5 fetal Wt (left) 
and BMpRIAcon-ko (right) thymocytes. (C) Graph representing DN1 and DN2 mean percentages in e13.5 fetal Wt (open bars) and BMpRIAcon-ko (dark 
bars) thymi. Wt n = 5, BMpRIAcon-ko n = 3. (D) Graph representing mean relative number of cells recovered from e14.5 Wt (open bar) and BMpRIAcon-ko 
(dark bar) thymus (Wt and BMpRIAcon-ko n = 3). (E) Graph representing mean cell numbers at DN1 to DN4 subsets recovered from e14.5 fetal Wt (open 
bars) and con-ko (dark bars) thymi. Standard errors of the mean shown (Wt and BMpRIAcon-ko, n = 3). (F) FACS profiles of CD44 and CD25 cell surface 
expression in e14.5 fetal Wt (left) and BMpRIAcon-ko (right) thymocytes. on every quadrant mean percentage values +/− standard errors are shown. (G) 
Graph representing mean number of cells recovered from e15.5 (open bar) and BMpR1Acon-ko (dark bar) thymi. Standard error of the mean shown (Wt 
n = 10 and BMpRIAcon-ko, n = 7). on all graphs, standard errors of the mean are shown. Statistically significant differences (*P < 0.05, **P < 0.10, Student 
t test) are indicated with stars.
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Nevertheless the development of BMPRIAcon-ko thymocytes 
by BMP4 treatment was less affected than that of their WT 
counterparts, as demonstrated by the statistically significant 
decrease in percentage of DN cells relative to control FTOCs 
in BMPRIAcon-ko compared with WT BMP4-treated FTOCs 
(Fig. 6A), indicating that a combination of thymocyte/hemato-
poietic intrinsic and stromal factors are responsible for the trans-
duction of excess BMP signaling at this stage.
Treatment of FTOCs with BMP2/4 antagonist Noggin has 
revealed a physiological role for endogenous BMP2/4 signal-
ing in thymocyte development, and we have previously shown 
that Noggin treatment of FTOCs accelerated DN thymocyte 
maturation.9 We compared the development of thymocytes in 
control and Noggin-treated WT and BMPRIAcon-ko E14.5 
FTOCs. We found that while Noggin significantly acceler-
ated DN to DP transition of WT thymocytes, (Fig. 6B, upper 
panel and Fig. 6C), it did not affect subset composition of 
BMPRIAcon-ko FTOCs (Fig. 6B, lower panel and Fig. 6C). 
Therefore we conclude that in the thymus, under physiological 
conditions, endogenous BMP2/4 signals directly to developing 
thymocytes through BMPRIA to negatively regulate DN to DP 
transition.
Discussion
We investigated the physiological role 
of BMP2/4 signaling during thymocyte 
development, via targeted deletion of 
BMPRIA expression in thymocytes. We 
showed that BMPRIB and ALK2 were 
not expressed in thymocytes. Deletion 
of BMPRIA expression therefore resulted 
in thymocytes that were unable to 
receive and respond to BMP2/4 signal-
ing, enabling us to distinguish between 
the indirect effect of the signal received 
by the thymus stroma from the effect of 
signal received directly by the developing 
thymocytes.
Our results, in accordance with previ-
ously published studies,9-12,19 indicate that 
BMP2/4 signaling is necessary for normal 
developmental kinetics of fetal thymo-
cytes at 2 distinct developmental stages: 
the transition from DN1 to DN3, and 
from DN to DP cell. We show that the 
effects of the signaling are dose-depen-
dent at the transition from DN1 to DN3, 
and that different doses can have oppos-
ing consequences on development. We 
showed that at the transition from DN1 
to DN3, while the physiological level of 
signaling is required for efficient differen-
tiation, as indicated by the reduced num-
ber of DN3 and DN4 cells in the E14.5 
BMPRIAcon-ko thymi (Fig. 3D and E), 
an artificially elevated BMP4 signal has 
the opposite effect and results in devel-
opmental arrest at the DN1 stage (Fig. 5 
and refs. 9 and 11). The observed delay at 
E14.5, when DN3 cells first develop and 
not at E13.5 when the thymus is exclu-
sively composed of DN1 and DN2 cells, 
is consistent with our previous findings 
that BMP2/4 signaling is involved at the 
DN1 to DN3 transition.9
At the DN to DP transition, how-
ever, physiological BMP2/4 signaling 
Figure 4. Analysis of e16.5 and e15.5 +7 d in culture fetal BMpRIAcon-ko and Wt thymi. (A) Graph 
representing mean number of thymocytes recovered from e16.5 Wt (open bar, n = 16) and 
BMpRIAcon-ko (dark bar, n = 14) thymi. (B) Graph representing DN1 to DN4 mean percentages of 
the DN thymocytes in e16.5 fetal Wt (open bar, n = 16) and BMpRIAcon-ko (dark bar, n = 14) thymi. 
(C) Graph representing mean percentages of DN, CD8ISp, Dp, and CD4Sp thymocytes in e16.5 fetal 
Wt(open bar, n = 16) and BMpRIAcon-ko (dark bar, n = 14) thymi. (D) Graph representing the mean 
fold difference in cell numbers of fresh e15.5 lobes to those cultured for 7 d (Wt open bar n = 5 
and BMpRIAcon-ko dark bars n = 2). (A–D) on all graphs, standard errors of the mean are shown. 
Statistically significant differences (P < 0.05, Student t test) are indicated with stars. (E) FACS profiles 
of CD4 and CD8 cell surface expression in thymocytes from Wt (left) and BMpRIAcon-ko (right) e15.5 
+7 d FtoCs. on every quadrant percentage is shown.
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is a negative regulator of DN to DP development, since 
removal of the signal by conditional deletion of BMPRIA, 
or by Noggin-treatment, promotes thymocyte expansion 
to the DP stage. In contrast, exogenous BMP4 delays 
development from DN to DP. Therefore, our data shows 
that physiological BMP2/4 signaling is necessary for nor-
mal thymocyte number at the earlier stages of thymocyte 
development, to maintain a normal progenitor pool, and 
supports previous findings9-11 indicating that the physi-
ological BMP2/4 signal negatively regulates the transition 
from DN to DP.
We did not detect an effect on thymocyte composition 
and cell number in the adult BMPRIAcon-ko thymus. This 
could be attributed either to the low level of expression of 
BMPRIA in adult thymocytes, meaning that BMPRIA is 
not important for adult thymocyte development (Fig. 1B), 
or to the opposing effects of BMP2/4 at consecutive devel-
opmental stages, masking impact of deletion in the steady-
state adult thymus. In the fetus, we analyzed consecutive 
developmental days, and while we observed no defect in 
homing of BMPRIA-deficient thymocytes (day E13.5, 
Fig. 3A–C), development to the DN3 stage was initially 
delayed (E14.5, Fig. 3D–F), but thymocyte expansion and 
development to DP stage was accelerated, so thymocyte 
numbers and development caught up by E16.5 (Fig. 4).
Development of BMPRIAcon-ko DN1 thymocytes was 
arrested by BMP4 treatment, indicating that the effect 
of BMP4 signaling to the thymocytes is, at least partly, 
indirect, by signaling to other cell types in the thymus 
(stroma including epithelial and other non-hematopoietic 
cell types). Interplay between BMP2/4 regulated stromal 
factors and the developing thymocytes must cause the 
observed developmental block. We also showed that the 
developmental arrest of BMPRIAcon-ko thymocytes by 
BMP4-treatment was significantly less than in WT thy-
mocytes, as indicated by the reduced ratio of DN1/DN3 
in the BMPRIAcon-ko BMP4-treated FTOCs compared 
with their WT counterparts. Taken together, our data indi-
cates that the BMPRIAcon-ko thymocytes do not respond 
to BMP4 treatment as strongly as their WT counterparts, 
and therefore that high dose BMP2/4 signaling for devel-
opmental arrest affects thymocyte transition from DN1 to 
DN3 both via direct signaling to the thymocytes as well as 
indirectly via the stroma.
Our data from Noggin treated WT and BMPRIAcon-ko 
FTOCs shows that, at the transition from DN to DP, 
physiological BMP2/4 negatively regulates differentiation 
by acting directly on thymocytes in a BMPRIA-dependent 
manner, and not via the stroma. BMPRIA-deficient thy-
mocytes were refractory to Noggin treatment, whereas 
WT thymocytes differentiated faster.
In brief, our findings provide novel insight into the 
physiological role of BMP2/4 signaling during thymocyte 
development and distinguish the direct effects on thymo-
cytes from indirect effects via the thymus stroma. We show 
that physiological BMP2/4 signaling positively regulates 
Figure  5. BMp4 treatment of Wt and BMpRIAcon-ko FtoCs. (A) typical FACS 
profiles of CD44 and CD25 cell surface expression in DN thymocytes recovered 
from Wt (top, n = 9) and BMpRIAcon-ko (bottom, n = 5) control (left) or BMp4 
treated (right) FtoCs, cultured for 3 d. (B) Graph representing mean percent-
ages of DN1-DN4 thymocytes in Wt control, BMpRIAcon-ko control, Wt BMp4-
reated, and BMpRIAcon-ko BMp4-treated FtoCs. (C) Graph representing DN1/
DN3 cell ratios in Wt control, Wt BMp4 treated, BMpRIAcon-ko control and 
BMpRIAcon-ko BMp4 treated FtoCs (Wt n = 9, BMpRIAcon-ko n = 5). on all 
graphs, error bars shown represent standard error of the mean. Statistically sig-
nificant differences (P < 0.05, Student t test) are indicated with stars.
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fetal thymocyte development from DN1 to DN3 
stage, both directly and indirectly via the thymus 
stroma, and negatively regulates DN to DP tran-
sition via direct signaling to the thymocytes.
Materials and Methods
Mice
C57BL/6 mice, purchased from B and K 
Universal, and Vav-Cre transgenic mice, a gift 
from Dimitris Kioussis, backcrossed on C57BL/6, 
and BMPRIA-floxP mice22 (backcrossed onto 
C57BL/6) were bred and maintained at Imperial 
and University College London, according to UK 
Home Office regulations. Timed mates were per-
formed as described.25
Quantitative RT-PCR analysis
C57BL/6J E16.5 fetal and adult thymocytes 
were sorted on a Modular Flow Cytometer 
(MoFlo, Cytomation, Inc) at the Cancer 
Research UK FACS laboratory. For purification 
of DN1–DN4 populations, cells falling within 
the FSC/SSC live gate, >98% of which were 
CD45.2+, were sorted using antibodies directed 
against CD25FITC, CD44PE, and CD3/
CD4/CD8Cychrome. For DP and SP popula-
tions thymocytes were stained with CD4PE and 
CD8Cychrome. Purity of all populations was 
>98%.
Selection of Thy1.2 positive thymocytes for 
quantitative RT-PCR analysis shown in Fig. 2D 
was performed with the EasySep™ Mouse PE 
Positive Selection Kit and EasySep™ Magnet 
(StemCell Technologies). Approximately 3 × 108 
WT and BMPRIAcon-ko adult thymocytes were 
stained with anti-Thy1.2 antibody conjugated 
with PE and then Thy1.2+ thymocytes were posi-
tively selected following manufacturer’s instruc-
tions. Purity of selected population was tested by 
flowcytometry and found to be >99.7%.
Quantitative RT-PCR was as described.26 
In brief, RNA was extracted from sorted thy-
mocytes with the Absolutely RNA miniprep 
kit (Stratagene), cDNA synthesized with 
SuperscriptIII (Invitrogen) and random prim-
ers and the cDNA samples analyzed in triplicate 
by quantitative (q)PCR on an iCycler (Bio-
Rad Laboratories) using the iQ™SYBR® Green 
Supermix (Bio-Rad) following manufacturer’s 
instructions. The primers used for the qRT-
PCR are listed in Table 1. All primer sets were 
designed to span over 2 different exons, to avoid 
amplification from genomic DNA contami-
nation. For each sample, gene of interest was 
normalized to HPRT and standard errors were 
calculated.
Figure 6. BMp4 and Noggin treatments of Wt and BMpRIAcon-ko FtoCs. (A) e14.5 Wt and 
BMpRIAcon-ko FtoCs treated with BMp4 or without (control) for 3 d. Graph representing 
percentages of cells in DN, CD8ISp and Dp subsets in Wt (open bars) and BMpRIAcon-ko 
(dark bars) treated relative to control FtoCs. (B) FACS profiles of CD4 and CD8 cell sur-
face expression in e14.5 Wt (upper) and BMpRIAcon-ko (lower) FtoCs treated with Noggin 
(+Noggin, right -panels) or without (control, left panel) for 3 d. (C) Graph representing 
percentages of DN, CD8ISp, Dp, and CD4Sp thymocytes in Wt control, Wt Noggin-treated, 
BMpRIAcon-ko control, and BMpRIAcon-ko Noggin-treated FtoCs. Wt n = 5, BMpRIAcon-ko 
n = 4. on all graphs, error bars shown represent standard error of the mean. Statistically sig-
nificant differences (P < 0.05, Student t test) are indicated with stars.
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Microarray data analysis
Gene-expression microarray data sets from 
the Immgen Database21 (Geo Dataseries: 
GSE15907, performed on Affymetrix Mouse 
Gene 1.0 ST Platform [GPL6246] using RNA 
from double sorted developmental T-cell 
populations from 6-week-old adult mice hav-
ing- >99% purity with 3 different samples 
for each population) were analyzed using R. 
Package “affy” was used for quality control 
and normalization of the data set by log-scale 
robust multi-array analysis (RMA). Probe-set 
hybridization intensity values thus obtained 
were unlogged and used to plot expres-
sion of different genes like Smad7 and Alk2 
relative to Hprt in DN1-DN4, DP, and CD4+SPCD69+ and 
CD8+SPCD69+ thymocyte populations. Immgen Database 
threshold of 120 was used to indicate positive expression (at 
95% confidence).
BMP4 and noggin treatments of fetal thymic organ cultures 
(FTOCs)
Thymi from WT and BMPRIAcon-ko E14.5 embryos were 
cultured on Millipore filters (0.8-μm pore size) (Millipore) in 
AIM-V serum-free lymphocyte medium (Life Technologies). 
Each FTOC consisted of one fetal thymus lobe. Human recom-
binant BMP4 and recombinant Noggin-Fc fusion protein were 
purchased from R&D Systems. For BMP4 and Noggin treat-
ments, the 2 lobes from every fetus were separated and one was 
cultured in AIM-V and the other in AIM-V+BMP4 (0.1 μg/ml) 
or AIM-V+Noggin (0.5 μg/ml) for 72 h. Therefore each treated 
FTOC corresponded to a control FTOC thymus lobe from the 
same embryo.
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Mouse genotyping
Embryos and animals were genotyped by PCR as described.27 
In brief, DNA was extracted from tissue biopsies by digesting 
in lysis buffer containing 50 mM KCl, 1.5 mM MgCL2, 10 
mM Tris HCL (pH 8.5), 0.01% gelatin, 0.45% Nonident P-40, 
0.45% Tween 20, and 0.5 µg/ml proteinase K (Sigma-Aldrich) 
overnight at 58 °C. ~50 ng of DNA was used as a template in each 
PCR reaction. Primers for Vav-Cre genotyping: CreForward: 
AGATGCCAGG ACATCAGGAA CCTG and CreReverse: 
ATCAGCCACA CCAGACACAG AGATC. BMPRIAfloxP 
genotyping was performed with primers fx2: GCAGCTGCTG 
CTGCAGCCTC C and fx4: TGGCTACAAT TTGTCTCATG 
C.28 BMPRIAcon-ko mice were BMPRIAflox/flox VavCre+. 
WT Bmpr1a allele produced a longer PCR product compared 
with Bmpr1a flox allele.
Flow cytometry and antibodies
Flow cytometry and staining were as described:29 thymocyte 
suspensions were stained using combinations of directly conju-
gated antibodies obtained from BD PharMingen or e-biosciences 
for 30 min on ice in 50 μl Dulbecco modified medium (Life 
Technologies), supplemented with 2% FCS and 0.01% sodium 
azide. Cells were washed in this medium between incubations 
and prior to analysis on the FACScan (Becton Dickinson). 
Events were collected in list mode using CellQuest software and 
data analyzed using CellQuest Pro software. Live cells were gated 
according to their FSC and SSC profiles.
Table 1. primers used for quantitative Rt-pCR analysis 
Gene Primer name Sequence
Bmpr1a
1AF tGGGAGCCtG tCtGttCAtC
1AR GCAAGGtAtC CtCtGGtGCt AAAG
Bmpr1b
1BF GCtGAAtCAC AACCAtttGG CG
1BR CtCtCCAtCC tCCttCttGG
Bmpr2
BMpRIIF CGtGttAtGG tCtGtGGGAG
BMpRIIR AttGAGGGtG GGGtGGtAG
Alk2 QuantiTECT primer assay, QIAGEN
Hprt
F53333 tGAttAtGGA CAGGACtGAA AG
F53334 GGtCAGCAAA GAACttAtAG CC
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